Clinical trial
Phase 3 Prospective, Multicenter, Double-blind, Randomized, Active Control Study to Demonstrate Safety & Effectiveness of Neutrolin in Preventing Catheter-related Bloodstream Infection in Subjects on Hemodialysis for End Stage Renal Disease
NCT02651428 is registered in ClinicalTrials.gov with CorMedix Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 3 Prospective, Multicenter, Double-blind, Randomized, Active Control Study to Demonstrate Safety & Effectiveness of Neutrolin in Preventing Catheter-related Bloodstream Infection in Subjects on Hemodialysis for End Stage Renal Disease
- Lead sponsor
- CorMedix Therapeutics
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 31, 2015
- Completion date
- October 31, 2018
- Enrollment
- 806 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.